Investment Summary

In August 2018 Quethera, a spin-out from the University of Cambridge, was acquired by Astellas Pharma Inc. Under the terms of the purchase agreement, Astellas may pay up to £85 million in aggregate consideration (upfront and contingent payments) to Quethera shareholders as described here.

Quethera is a gene therapy company developing a novel treatment for glaucoma, developing methods to deliver gene products for neuroprotectants and their receptors directly to the eye, which will provide long term neuroprotection to the retinal ganglion cells (RGC) in the eye, preventing their death and visual field loss. Retinal ganglion cell death is the ultimate conclusion in glaucoma and is what causes loss of sight in sufferers.